HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zinc Chloride, SLS Dental Rinse Combo Needs More Efficacy Data

This article was originally published in The Rose Sheet

Executive Summary

The ingredient combination of zinc chloride, sodium citrate, hydrogen peroxide and sodium lauryl sulfate is Category I for safety, but efficacy data for the dental rinse combo are insufficient to determine its effectiveness for antiplaque/antigingivitis claims, FDA's Dental Plaque Subcommittee recommended unanimously at the group's final meeting in Rockville, Md. Dec. 2-3.

You may also be interested in...

Zinc Citrate Clinical Data Support Category I Efficacy - Colgate

Data from a double-blind, stratified six-month clinical study on the efficacy of zinc citrate in reducing plaque and gingivitis support Category I classification of the ingredient, Colgate-Palmolive states.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts